Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Implementation of a High-Throughput Automated Comprehensive Genomic Profiling Test: TruSight Oncology 500 HT.
Ball M, Romanovsky E, Schnecko F, Kirchner M, Neumann O, Brandt R, Beck S, Seker-Cin H, Kluck K, Ourailidis I, Goldschmid H, Fink A, Volckmar AL, Menzel M, Allgäuer M, Schirmacher P, Budczies J, Stenzinger A, Kazdal D. Ball M, et al. Among authors: volckmar al. J Mol Diagn. 2024 Dec 12:S1525-1578(24)00305-2. doi: 10.1016/j.jmoldx.2024.11.005. Online ahead of print. J Mol Diagn. 2024. PMID: 39674366 Free article.
Pathology in the legal framework of European and German medical device law: Operation, use and in-house manufacture of in vitro diagnostic medical devices.
Kahles A, Goldschmid H, Volckmar AL, Kazdal D, Gassner UM, Vogeser M, Brüggemann M, Bürrig KF, Kääb-Sanyal V, Flechtenmacher C, Schirmacher P, Stenzinger A. Kahles A, et al. Among authors: volckmar al. Ger Med Sci. 2024 Oct 11;22:Doc09. doi: 10.3205/000335. eCollection 2024. Ger Med Sci. 2024. PMID: 39559338 Free PMC article. Review.
Corrigendum to "First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations" [Eur J Cancer 199 (2024) 113556].
Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, Kazdal D, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, Kirchner M, Volckmar AL, Kopp HG, Allgäuer M, Grohé C, Tufman A, Reck M, Frost N, Stenzinger A, Thomas M, Christopoulos P. Blasi M, et al. Among authors: volckmar al. Eur J Cancer. 2024 Jul;205:114130. doi: 10.1016/j.ejca.2024.114130. Epub 2024 May 24. Eur J Cancer. 2024. PMID: 38789333 No abstract available.
Leveraging Off-Target Reads in Panel Sequencing for Homologous Recombination Repair Deficiency Screening in Tumor.
Ball M, Ourailidis I, Kluck K, Menzel M, Kirchner M, Allgäuer M, Tay TKY, Schnecko F, Volckmar AL, Goldschmid H, Neuman O, Fröhling S, Schirmacher P, Budczies J, Stenzinger A, Kazdal D. Ball M, et al. Among authors: volckmar al. J Mol Diagn. 2024 Jun;26(6):479-486. doi: 10.1016/j.jmoldx.2024.02.008. Epub 2024 Mar 22. J Mol Diagn. 2024. PMID: 38522840 Free article.
Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.
Menzel M, Kirchner M, Kluck K, Ball M, Beck S, Allgäuer M, Assmann C, Schnorbach J, Volckmar AL, Tay TKY, Goldschmid H, Tan DS, Thomas M, Kazdal D, Budczies J, Stenzinger A, Christopoulos P. Menzel M, et al. Among authors: volckmar al. J Pathol Clin Res. 2024 Mar;10(2):e354. doi: 10.1002/cjp2.354. J Pathol Clin Res. 2024. PMID: 38284983 Free PMC article.
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, Kazdal D, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, Kirchner M, Volckmar AL, Kopp HG, Allgäuer M, Grohé C, Tufman A, Reck M, Frost N, Stenzinger A, Thomas M, Christopoulos P. Blasi M, et al. Among authors: volckmar al. Eur J Cancer. 2024 Mar;199:113556. doi: 10.1016/j.ejca.2024.113556. Epub 2024 Jan 17. Eur J Cancer. 2024. PMID: 38271745 Free article.
Regulation (EU) 2017/746 (IVDR): practical implementation of annex I in pathology.
Kahles A, Goldschmid H, Volckmar AL, Ploeger C, Kazdal D, Penzel R, Budczies J, Flechtenmacher C, Gassner UM, Brüggemann M, Vogeser M, Schirmacher P, Stenzinger A. Kahles A, et al. Among authors: volckmar al. Pathologie (Heidelb). 2023 Nov;44(Suppl 2):86-95. doi: 10.1007/s00292-023-01274-6. Epub 2023 Dec 4. Pathologie (Heidelb). 2023. PMID: 38047950 Free PMC article. Review.
[Regulation (EU) 2017/746 (IVDR): practical implementation of annex I in pathology].
Kahles A, Goldschmid H, Volckmar AL, Ploeger C, Kazdal D, Penzel R, Budczies J, Flechtenmacher C, Gassner UM, Brüggemann M, Vogeser M, Schirmacher P, Stenzinger A. Kahles A, et al. Among authors: volckmar al. Pathologie (Heidelb). 2023 Nov;44(6):381-391. doi: 10.1007/s00292-023-01231-3. Epub 2023 Oct 4. Pathologie (Heidelb). 2023. PMID: 37792098 Free PMC article. Review. German.
Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.
Seker-Cin H, Tay TKY, Kazdal D, Kluck K, Ball M, Neumann O, Winter H, Herth F, Heußel CP, Savai R, Schirmacher P, Thomas M, Budczies J, Allgäuer M, Christopoulos P, Stenzinger A, Volckmar AL. Seker-Cin H, et al. Among authors: volckmar al. Lung Cancer. 2023 Oct;184:107317. doi: 10.1016/j.lungcan.2023.107317. Epub 2023 Jul 27. Lung Cancer. 2023. PMID: 37586177
Structure and content of the EU-IVDR : Current status and implications for pathology.
Kahles A, Goldschmid H, Volckmar AL, Ploeger C, Kazdal D, Penzel R, Budczies J, Kempny G, Kazmierczak M, Flechtenmacher C, Baretton G, Weichert W, Horst D, Klauschen F, Gassner UM, Brüggemann M, Vogeser M, Schirmacher P, Stenzinger A. Kahles A, et al. Among authors: volckmar al. Pathologie (Heidelb). 2023 Nov;44(Suppl 2):73-85. doi: 10.1007/s00292-022-01176-z. Epub 2023 Feb 3. Pathologie (Heidelb). 2023. PMID: 36735063 Free PMC article. Review.
96 results